Blood Glucose Control Management Research Articles

Identifying Factors Which Enhance the Self-Management of Type 2 Diabetes: A Systematic Review with Thematic Analysis

BACKGROUND: Individuals with type 2 diabetes play a pivotal role in their health. Enhancing the self-management of diabetes can improve blood glucose control, and quality of life, and reduce diabetes-related complications. We have identified factors influencing the self-management of type 2 diabetes to inform strategies that may be applied in the long-term management of blood glucose control.
 
 METHODS: We conducted a systematic literature review of recent studies published between January 2010 to December 2020 to identify the available evidence on effective self-management strategies for type 2 diabetes. The databases used for the searchers were Scopus, PubMed, Science Direct, CINAHL, and Google Scholar. We assessed English language publications only. The screening of titles was duplicated by two researchers. We then conducted a thematic analysis of the key findings from eligible publications to identify reoccurring messages that may augment or abate self-management strategies.
 
 RESULTS: We identified 49 relevant publications involving 90,857 participants. Four key themes were identified from these publications: Individual drive, social capital, Knowledge base, and Insufficient health care. High motivation and self-efficacy enabled greater self-management. The importance of family, friends, and the health care professional was salient, as were the negative effects of stigma and labelling. Enablers to good self-management were the level of support provided and its affordability. Finally, the accessibility and adequacy of the health care services emerged as fundamental to permit diabetes self-management.
 
 CONCLUSIONS: Self-management of type 2 diabetes is an essential strategy given its global presence and impact, and the current resource constraints in health care. Individuals with type 2 diabetes should be empowered and supported to self-manage. This includes awareness raising on their role in self-health, engaging broader support networks, and the pivotal role of health care professionals to inform and support. Further research is needed into the capacity assessment of healthcare systems in diabetes medicine, targeted low-cost resources for self-management, and the financial requirements that enable self-management advice to be enacted.

Cost-effectiveness analysis of comprehensive intervention programs to control blood glucose in overweight and obese type 2 diabetes mellitus patients based on a real-world setting: Markov modeling

Blood glucose control management in overweight and obese diabetic patients poses heavy public health and economic burdens on the health system. This study aimed to evaluate the short-term cost-effectiveness of a comprehensive intervention program for blood glucose management in different groups using a Markov model. Based on real-world data, a Markov model was developed to calculate the cost per quality-adjusted life-year (QALY) gained. The division of Markov states was in accordance with clinical practice. A three-month cycle length and a 5-year time horizon were applied. A 3% discounting rate was applied for both the costs and utilities. The incremental cost-effectiveness ratios (ICER) was more favorable for the male group than the female group, with an associated ICER of 104 K RMB per QALY gained. Compared with the younger group, the incremental gain of the middle-aged group was -0.062 QALY, and the incremental cost was -3,198.64 RMB; meanwhile, the incremental gain of the elderly group was -0.176 QALY, and the incremental cost was 4,485.746 RMB. The sensitivity analysis showed that the ICER is sensitive to the costs of this program and less sensitive to the discounting rate and the time horizon. The comprehensive intervention program for blood glucose management of overweight and obese patients with diabetes is cost-effective for the middle-aged male group and elderly female group, respectively. Moreover, the male group was more favorable than the female group if three times the gross domestic product (GDP) per capita was adopted as the maximum willingness to pay (WTP) for a QALY in China.

Why should people with type 1 diabetes exercise regularly?

Plethoric evidence reminds of the protective effects of exercise against a number of health risks, across all ages, in the general population. The benefits of exercise for individuals with type 2 diabetes are indisputable. An in-depth understanding of energy metabolism has reasonably entailed exercise as a cornerstone in the lifestyle of almost all subjects with type 1 diabetes. Nevertheless, individuals with type 1 diabetes often fail in accomplishing exercise guidelines and they are less active than their peer without diabetes. Two major obstacles are feared by people with type 1 diabetes who wish to exercise regularly: management of blood glucose control and hypoglycemia. Nowadays, strategies, including glucose monitoring technology and insulin pump therapy, have significantly contributed to the participation in regular physical activity, and even in competitive sports, for people with type 1 diabetes. Novel modalities of training, like different intensity, interspersed exercise, are as well promising. The beneficial potential of exercise in type 1 diabetes is multi-faceted, and it has to be fully exploited because it goes beyond the insulin-mimetic action, possibly through immunomodulation.

Is There Evidence of Any Safety Differences Among DPP-4 Inhibitors in the Treatment of People with Type 2 Diabetes Mellitus and Reduced GFR Due to Chronic Kidney Disease?

Is There Evidence of Any Safety Differences Among DPP-4 Inhibitors in the Treatment of People with Type 2 Diabetes Mellitus and Reduced GFR Due to Chronic Kidney Disease?

A Pharmacological/Physiological Comparison of Metformin and Exercise

Type 2 diabetes is a significant health concern in the United States and its prevalence is expected to triple by 2050. Both metformin and exercise have shown to be effective in the management of blood glucose control. The pharmacological mechanism of action of metformin is largely based on the activation of AMPK to induce glucose transport. Likewise, the physiological actions of exercise appear to be a potent activator of AMPK, resulting in glucose uptake by the muscle. Research shows that metformin may control blood glucose slightly better than exercise in persons with type 2 diabetes. However, it appears that lifestyle interventions outperform metformin when trying to prevent the onset of diabetes. Both metformin and exercise have a positive and significant role in the management of type 2 diabetes and appear to work similarly to help manage blood glucose control.

Glucose management in the neurosurgical patient: are we yet any closer?

This review focuses on recent findings in perioperative management of blood glucose control using intensive insulin therapy in neurosurgical and neurocritical care and in other intensive care unit patients. We also aim to address practical issues and make recommendations that may contribute to the safe clinical application of intensive insulin therapy targeted to optimize blood glucose control in these patients. Intensive insulin therapy targeted to obtain tight blood glucose control induces a substantial increase in the number of hypoglycemic episodes and mortality rate. On the contrary, hyperglycemia--both isolated episodes and high mean glucose levels--is associated with worsened neurologic outcome and increased mortality. In neurosurgical and neurocritical care as well as other intensive care unit patients, both hypoglycemia and hyperglycemia have significant adverse effects. The optimal glucose level remains under debate but significant steps have evolved with the call for judicious control and elimination of the historical approach to glycemic management, which underestimated drawbacks associated with dysglycemia. The increased incidence of hypoglycemia and mortality as well as the impact of hyperglycemia on worsening neurologic function in patients with acute brain damage heightens the need for more clinical studies on perioperative glucose management in these patients.

Traitements futurs de l'insulino-résistance

Present treatment strategies of type 2 diabetes are unsatisfactory. At diagnosis, most oral antidiabetic agents are effective on blood glucose control, but with time metabolic control deteriorates whatever therapeutic modality is used. The reasons for treatment failure are the natural history of the disease and the necessary implication of the patient in the management of blood glucose control on a constant basis. News treatments thus have to be developed acting on either insulin resistance or insulin secretion or both. We discuss here present and future developments which aim to decrease insulin resistance. In the last 10 years, multiple therapeutic targets have been identified in appetite control, such as the endocannabinoid system and glucagon-like-peptide 1, in insulin signalling and in the control of cellular energy balance such as AMP kinase. These developments should allow a better management of type 2 diabetes and its complications.

Assessing Glycemia in Diabetes Using Self-monitoring Blood Glucose and Hemoglobin A1c

With the increasing prevalence of diabetes, successful management of blood glucose control is increasingly important. Current approaches to assessing glycemia include the use of self-monitoring of blood glucose (SMBG) and hemoglobin A1c (HbA1c). To assess the evidence underlying the use of these 2 modalities, to evaluate confounders and sources of error in each test, to describe upcoming developments, and to reach evidence-based conclusions on their optimal use. Reports identified from MEDLINE searches (1976-2005) using relevant terms were selected for quality and relevance to the stated questions. Particular attention was paid to larger cohort studies, clinical trials, meta-analyses, and established recommendations. If used properly SMBG gives an acceptably accurate reflection of immediate plasma glucose levels. Study results vary, but in general, the evidence supports a positive effect of regular SMBG for improving glycemia, particularly in individuals treated with insulin. The best timing of SMBG and its frequency are controversial issues, but the clinical recommendation is for regular monitoring with frequency depending on the treatment and the instability of glycemia. In the relatively near term, SMBG could gradually be replaced by continuous glucose monitoring. HbA1c measures long-term glycemic control, reflecting a time-weighted mean over the previous 3 to 4 months. There are a number of physiologic and methodologic confounders that can affect HbA1c, but standardization of assays has been well established. The main value of HbA1c is its use as a predictor of diabetic complications and the proven effect of improved control of HbA1c on complication risk. A reasonable target value for HbA1c is less than 7%. A new method for measuring HbA1c may cause significant changes in the recommended levels, the numbers reported, and even the name of the test. Assessing glycemia in diabetes can be a challenge, but approaches are available that promote successful management of blood glucose and may thereby lead to a significant reduction in morbidity and mortality related to diabetes.

Factors influencing the natural history of diabetic retinopathy.

Despite recent improvements in the management of blood glucose control and in modern technology such as laser treatment and vitreoretinal surgery, diabetes mellitus is the major systemic cause of blindness in the Western world. The study of the natural history of diabetic retinopathy is difficult because of the variability of the disease, and the numerous factors that may influence its course and outcome. In the many studies available of the natural history of diabetic retinopathy, there is a failure to identify these factors. This article tries to identify and to classify the influences that may modify the outcome and the natural course of diabetic retinopathy, and gives some advice on how to deal with them. They can be subdivided into external, internal and ocular factors. Any future studies of the natural history of diabetic retinopathy are marred by the fact that effective treatment is now established and the guidelines for when to commence treatment and the techniques of treatment are well documented.